Clinical trial
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's…
NCT00014560 · Dartmouth-Hitchcock Medical Center, Other · Terminated
Key facts
| NCT number | NCT00014560 |
|---|---|
| Title | Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia |
| Official title | Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL) |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological |
| Interventions | bispecific antibody 4G7xH22, sargramostim |
| Enrollment | 3 |
| Start date | Sep 28, 2000 |
| Primary completion | Feb 14, 2003 |
| Completion | Feb 14, 2003 |
| First posted | Jul 30, 2003 |
| Last update posted | May 3, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: